Side-by-side comparison: effects, dosing ranges, side effects, regulatory status, and reconstitution.
Peptide A
Healing & Recovery
Tissue-protective helix-B fragment of erythropoietin — without the red-blood-cell effects.
Peptide B
Healing & Recovery
Gastric pentadecapeptide with broad tissue-healing properties.
Typical vial
8 mg
Typical dose
2,000-8,000 mcg
Half-life
~2 minutes (plasma); longer functional duration via receptor binding
FDA status
Not FDA approved. In clinical development by Araim Pharmaceu…
Typical vial
5 mg
Typical dose
250-500 mcg
Half-life
~4 hours (estimated from animal pharmacokinetic data)
FDA status
Not FDA approved for human use. FDA issued a warning letter …
ARA-290 (Cibinetide) effects
BPC-157 effects
ARA-290 (Cibinetide) side effects
BPC-157 side effects
ARA-290 (Cibinetide) dosing ranges
Small-fiber neuropathy / nerve healing
2-8 mg · Once daily (SubQ) · 4-12 weeks per cycle
General tissue protection research
1-4 mg · Daily or alternate-day · Per research protocol
BPC-157 dosing ranges
General tissue repair
250-500 mcg · Once or twice daily · 4-6 weeks
Gut healing
250-500 mcg · Twice daily (oral or SubQ) · 4-8 weeks
Acute injury recovery
500 mcg · Twice daily near injury site · 2-4 weeks
ARA-290 (Cibinetide): Tissue-protective helix-B fragment of erythropoietin — without the red-blood-cell effects. Typical dose 2,000-8,000 mcg. BPC-157: Gastric pentadecapeptide with broad tissue-healing properties. Typical dose 250-500 mcg. Both fall under the Healing & Recovery category.
Stacking ARA-290 (Cibinetide) with BPC-157 is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.
ARA-290 (Cibinetide) is typically dosed: Once daily (SubQ) for Small-fiber neuropathy / nerve healing; Daily or alternate-day for General tissue protection research. BPC-157 is typically dosed: Once or twice daily for General tissue repair; Twice daily (oral or SubQ) for Gut healing; Twice daily near injury site for Acute injury recovery.
ARA-290 (Cibinetide): Not FDA approved. In clinical development by Araim Pharmaceuticals. Granted orphan drug designation for sarcoidosis-related conditions. BPC-157: Not FDA approved for human use. FDA issued a warning letter in 2024 regarding compounded BPC-157 products.
Log doses, automate injection site rotation, and never lose track of where you last pinned. Free forever.
Get Started Free